Asia Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
Asia Pacific anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
Asia Pacific anti-vascular endothelial growth factor therapeutics market highlights
- The Asia Pacific anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 637.5 million in 2024.
- The market is expected to grow at a CAGR of -7.4% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Eylea is the most lucrative product segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2024 | USD 637.5 million |
| Market revenue in 2030 | USD 402.5 million |
| Growth rate | -7.4% (CAGR from 2024 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Eylea |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 4.4% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 9,124.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the Asia Pacific anti-vascular endothelial growth factor therapeutics market based on eylea covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to exhibit a significant CAGR over the forecast period due to increasing market opportunities and growing healthcare expenditure. Licensing agreements between companies and increasing demand for anti-VEGF products can support market growth over the coming years.
Furthermore, increase in initiatives undertaken by governments for improving health of population is expected to drive market growth during the forecast period. Improving access to anti-VEGF drugs through favorable reimbursement policies in high-income countries of Asia Pacific can fuel the market by boosting adoption.
In Australia, the inclusion of anti-VEGF products in the PBS can support market growth. However, the presence of generic players in the market can limit market growth.
Reasons to subscribe to Asia Pacific anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific anti-vascular endothelial growth factor therapeutics market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
